Total 40-50 patients:

Screening: Screening of patients for eligibility. Informed consent. Collection of trial relevant data and patient history.

Randomization


Day 1: Application of study treatment according to study protocol.

Day 2, i.e. 24 hours after application of study treatment:
Clinical assessment, VAS, SUPO Score, photo documentation.

5 – 7 days after application of study treatment:
Clinical assessment, VAS, SUPO Score, photo documentation. Evaluation of QoL by EORTC-QoL-C30 questionnaire and DLQI.

End of Study